A Study of GV20-0251 in Advanced or Refractory Solid Tumors

Sponsor
West China Hospital
Study ID
NCT07106827
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • GV20-0251 — DRUG
    Increasing doses of GV20-0251 administered by intravenous (IV) infusion once every 3 weeks

Study Details

This is a single-arm, single-center study for multiple tumor indications to evaluate the safety of GV20-0251. The trial uses a 3 + 3 design and enrolls 3-6 patients in the 10 mg/kg and 20 mg/kg dose groups, respectively. The cancer types include solid tumors.

Key Dates

First listed
Aug 6, 2025
Start date
Sep 4, 2025
Status verified
Nov 2025
Primary completion
Jun 11, 2027
Completion
Jun 11, 2028

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: GV20-0251 Treatment
    GV20-0251 safety in Advanced/Refractory Solid Tumors

Primary Outcome Measure

Evaluate GV20-0251 safety [ Time Frame: From Cycle 1 Day 1 dosing (each cycle is 21 days) until meeting the study termination criteria or 2 years ]

Central Contacts

Find similar trials

Nationwide
Endometrial cancer trialsHead and neck cancer trialsMelanoma trialsPancreatic cancer trialsOncology trialsGynecologic oncology trialsWomen's health trialsENT trialsSkin cancer trialsDermatology trialsGI oncology trials

Related Studies